209A.F · Catabasis Pharmaceuticals, Inc

-

Please sign in to comment on 209A.F

1 Comment

Admin

4 years, 1 month ago

Catabasis Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Catabasis Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 35.8% to $-9M since the same quarter in the previous year.

Finally, its free cash flow fell by 3.9% to $-8M since the same quarter in the previous year.

Based on the above factors, Catabasis Pharmaceuticals, Inc gets an overall score of 1/5.

Exchange	F
CurrencyCode	EUR
ISIN	None
Sector	Healthcare
Industry	Biotechnology

Market Cap	14M
PE Ratio	None
Target Price	None
Beta	1.66
Dividend Yield	None

ABOUT

Catabasis Pharmaceuticals, Inc

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.

209A.F · Catabasis Pharmaceuticals, Inc

-

Catabasis Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Catabasis Pharmaceuticals, Inc using a moving average strategy